Navigation Links
Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
Date:6/21/2013

HAYWARD, Calif., June 21, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) (the "Company"), a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases, today announced that it received a Staff Determination Letter (the "Notice") on June 19th, 2013 from the Nasdaq Stock Market LLC ("Nasdaq").

As previously disclosed, on December 20, 2012, the Nasdaq notified the Company that the bid price of the Company's listed common stock was not in compliance with the continued listing requirements due to the bid price closing at less than $1 per share over the previous 30 consecutive business days. Nasdaq has determined to remove the Company's common stock from listing and registration on the Nasdaq Stock Market, at the opening of business on June 28th, 2013.

The Company plans to appeal the Nasdaq Staff's determination to a Hearings Panel ("the Panel").  A hearing request will delay the suspension of the Company's common stock pending the Panel's decision.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, its intention to grant the underwriters an option to purchase additional shares and its intended use of proceeds from the offering.  Such statements are based on the Company's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as those set forth in the Company's public filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.  The Company disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510-856-5598.

 

 

 


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2019)... ... 14, 2019 , ... An October 4 article on US News ... tooth loss and heart disease. The researchers found that individuals between 40 and 79 ... having heart-related problems, compared to just seven percent for those who never lost any ...
(Date:10/11/2019)... , ... October 11, 2019 , ... ... regulated cannabis industry’s national resource — held the grand opening for Long Island’s ... STOA Wellness offers a thoughtfully curated lineup of CBD wellness products tailored to ...
(Date:10/10/2019)... ... ... Smile Brands Inc. together with its affiliate A+ Dental Care announced today ... A+ location in Natomas. , A+ Dental Care (“A+”) is a rapidly growing group ... dentists and three specialists work together as a team to provide comprehensive, personalized dental ...
Breaking Medicine Technology:
(Date:10/15/2019)... FALLS CHURCH, Va. (PRWEB) , ... October 15, ... ... Combination Products:, Complying with FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, ... does the recent Instructions for Use (IFU) guidance have on new drug applications ...
(Date:10/11/2019)... TEMECULA, Calif. (PRWEB) , ... October 11, 2019 , ... ... hills of Temecula, CA. The new location has incredible views of the Temecula Valley ... . On 2.5 acres, the new facility offers both private rooms as well as ...
(Date:10/10/2019)... ... October 10, 2019 , ... In attendance at ... excited to hear the significant results of an independent study presented by researchers ... The clinical study poster entitled “The Acute Effects of Citrulline Malate and Bonded ...
(Date:10/8/2019)... CA (PRWEB) , ... October 08, 2019 , ... Dr. ... gum disease in San Jose, CA experience relief from this common and treatable condition. ... in order to save adults from living with uncomfortable symptoms, including tender and bleeding ...
(Date:10/8/2019)... ... October 08, 2019 , ... Over the past three ... a standout in the sports restaurant category by providing a higher-quality product and experience ... fall menu as well as a "RAISE A MUG FOR THE CAUSE" campaign in ...
Breaking Medicine News(10 mins):